Fidelity Select Portfolios - Medical Technology and Devices Portfolio Profit Margin

The latest profit margin for FSMEX is -13.9% as of September 2023. That compares with -242.31% in the prior-year period — up 94.3% year over year. That is below the sector sector average of 19.74%. Investors often review this figure alongside Fidelity Select Portfolios - Medical Technology and Devices Portfolio's historical trend and sector peers before judging valuation or financial health.

Over the past year, FSMEX's profit margin moved from -242.31% to -13.9% — a 94.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Fidelity Select Portfolios - Medical Technology and Devices Portfolio's valuation or profitability profile.

Against its sector companies, FSMEX currently prints -13.9% for profit margin, while the sector average sits near 19.74%. That is roughly 170.4% below the sector mean. Large gaps often invite a closer look at Fidelity Select Portfolios - Medical Technology and Devices Portfolio's growth, margins, and balance sheet.

Profit Margin shows how effectively Fidelity Select Portfolios - Medical Technology and Devices Portfolio converts resources into returns. At -13.9%, FSMEX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -242.31% in the prior-year period — up 94.3% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting FSMEX's profit margin (-13.9%), review year-over-year change from -242.31%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.